ArticleGut microbes
Microcin MccI47 selectively inhibits enteric bacteria and reduces carbapenem-resistant
Article in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Engineered bacterial therapeutics from synthetic biology to clinical translation: A multi-database scientometric analysis, 2000-2026.Human vaccines & immunotherapeutics · 2026Review
- Gut microbiome dynamics in acute infectious diarrhea: A conceptual framework from acute dysbiosis toward precision restoration (Review).Experimental and therapeutic medicine · 2026Review
- Microbiome ecology and antibiotic treatment failure: resistance spread, microbial competition and community engineering.Microbial genomics · 2026Review
- Uncovering how selected potent bacteriocins reshape the broiler chicken gut microbiome in a PolyFermS continuous in vitro model.Journal of animal science and biotechnology · 2026Article
- A Non-genotoxic Variant of Escherichia coli Nissle 1917 EcN 2.0 Overexpressing Microcins Reduces Intestinal Carriage of ST131 ESBL-Producing Escherichia coli.Probiotics and antimicrobial proteins · 2026Article
- Prevalence and activity of class II microcins inApplied and environmental microbiology · 2026Article
- Microbiome-mediated colonization resistance to and countermeasures of Klebsiella pneumoniae.Nature communications · 2026Article
- Review
- Ec W: A Novel Narrow-Spectrum Class IIb Microcin from Escherichia coli.Probiotics and antimicrobial proteins · 2026Article
- From Microbial Switches to Metabolic Sensors: Rewiring the Gut-Brain Kynurenine Circuit.Biomedicines · 2025Review
- Antibacterial microcins are ubiquitous and functionally diverse across bacterial communities.Nature communications · 2025Article
- Non-antibiotic therapies for multidrug-resistant gastrointestinal infections: an overview of the use of probiotics, natural compounds, and bacteriophages.Frontiers in antibiotics · 2025Review
- Novel class IIb microcins show activity against Gram-negative ESKAPE and plant pathogens.eLife · 2024Article
- Living Engineered Bacterial Therapeutics: Emerging Affordable Precision Interventions.Microbial biotechnology · 2024Review
- Semantic search using protein large language models detects class II microcins in bacterial genomes.mSystems · 2024Article
- Low-Molecular-Weight Compounds Produced by the Intestinal Microbiota and Cardiovascular Disease.International journal of molecular sciences · 2024Review
- Bacteriocin diversity, function, discovery and application as antimicrobials.Nature reviews. Microbiology · 2024Review
- Commensal E. coli limits Salmonella gut invasion during inflammation by producing toxin-bound siderophores in a tonB-dependent manner.PLoS biology · 2024Article
- Effect of oral administration of microcin Y on growth performance, intestinal barrier function and gut microbiota of chicks challenged with Salmonella Pullorum.Veterinary research · 2024Article
- Commensal antimicrobial resistance mediates microbiome resilience to antibiotic disruption.Science translational medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gastrointestinal (GI) tract is the reservoir for multidrug resistant (MDR) pathogens, specifically carbapenem-resistant (CR)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.